Pere Mañé Appointed as CEO of Suanfarma, Ushering in New Era of Growth

Pere Mañé Appointed CEO of Suanfarma

Suanfarma, a global leader in developing, producing, and marketing active pharmaceutical ingredients and high-value CDMO services for the healthcare industry, has announced the appointment of Pere Mañé Godina as its new CEO, effective immediately. This strategic leadership change is poised to herald a new chapter for the company, focusing on industrial consolidation, sustainable innovation, and global expansion.

With a professional journey spanning over three decades, Pere brings extensive experience from various prominent pharmaceutical firms, including Uquifa, Boehringer Ingelheim, and Esteve Química. His career encompasses a spectrum of roles from technical and operational functions to executive positions such as General Manager and Group Chief Industrial Operations Officer. Recently, Mañé played a pivotal role in transforming the industrial landscape of Esteve, successfully positioning its chemical division as a global benchmark. His leadership led to Esteve being recognized as CDMO of the Year in the Small Molecules category at the 2025 Leadership Awards by DCAT, one of the industry's most prestigious accolades.

Pere’s appointment aligns seamlessly with Suanfarma's long-term strategic vision. Carlos Alonso, who has been serving as the interim CEO since October 2024, will ensure a smooth transition and continue to support the company in his new role as Executive Chairman.

“We firmly believe that Pere’s profound industry knowledge, strategic foresight, and leadership experience will be essential for reinforcing Suanfarma’s market position and continue to provide high-value solutions to our customers and partners,” said Alonso.

Pere's arrival is set to decisively influence Suanfarma's growth trajectory. His focus on operational excellence, advanced CDMO capabilities, and strategic partnerships will guide the company through the following phases:

1. Optimizing Industrial Operations: Streamlining processes and integrating cutting-edge technologies will be a key priority in enhancing operational efficiency.
2. Strengthening Global Relationships: Building and strengthening ties with global clients and key suppliers will facilitate broader market reach and enhanced collaboration.
3. Accelerating International Expansion: Mañé aims to rapidly increase Suanfarma's footprint in international markets, solidifying its presence worldwide.
4. Cultivating Innovation and Sustainability: Fostering a culture that emphasizes innovation and sustainability will be crucial for driving future developments.

In his own words, Pere Mañé shared, “Suanfarma has all the elements in place to lead the industry into the future—a solid foundation, a robust industrial platform, and a valuable international network supported by an exceptional team. I am excited to embark on this new journey and collaborate with everyone to deliver innovative, efficient, and sustainable solutions to our clients.”

Founded in 1993, Suanfarma operates in 70 countries and has been a part of Archimed, a specialized health investment firm, since 2021. As it continues to grow, Suanfarma aims to strengthen its commitment to delivering high-quality pharmaceutical ingredients while supporting the industry’s evolving needs.

For media inquiries, please visit Suanfarma's official site.